Advertisement
Screener

BRISTOL-MYERS SQUIBB COMPANY (BMY) Defined Contribution Plan, Cost

2.8 / 5 stars · 68/120 Roast Me

BRISTOL-MYERS SQUIBB COMPANY Defined Contribution Plan, Cost

BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Defined Contribution Plan, Cost of $325.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-02-11

  • BRISTOL-MYERS SQUIBB COMPANY defined contribution plan, cost for the quarter ending 2020-12-31 was $70.00M, a 16.67% increase year-over-year.
  • BRISTOL-MYERS SQUIBB COMPANY defined contribution plan, cost for the quarter ending 2020-09-30 was $70.00M, a 40.00% increase year-over-year.
  • BRISTOL-MYERS SQUIBB COMPANY defined contribution plan, cost for the quarter ending 2020-06-30 was $65.00M, a 30.00% increase year-over-year.
  • BRISTOL-MYERS SQUIBB COMPANY defined contribution plan, cost for the quarter ending 2020-03-31 was $85.00M, a 112.50% increase year-over-year.
  • BRISTOL-MYERS SQUIBB COMPANY defined contribution plan, cost for fiscal 2025 was $325.00M, a 17.72% decline from fiscal 2024.
  • BRISTOL-MYERS SQUIBB COMPANY defined contribution plan, cost for fiscal 2024 was $395.00M, a 3.95% increase from fiscal 2023.
  • BRISTOL-MYERS SQUIBB COMPANY defined contribution plan, cost for fiscal 2023 was $380.00M, a 5.56% increase from fiscal 2022.
  • BRISTOL-MYERS SQUIBB COMPANY defined contribution plan, cost for fiscal 2022 was $360.00M, a 2.86% increase from fiscal 2021.
Period endDefined Contribution Plan, Cost 3 monthDefined Contribution Plan, Cost 3 month as first filedDefined Contribution Plan, Cost 6 monthDefined Contribution Plan, Cost 9 monthDefined Contribution Plan, Cost 9 month as first filedDefined Contribution Plan, Cost 12 monthDefined Contribution Plan, Cost 12 month as first filed
2025-12-31$325.00M
10-K · filed 2026-02-11
2024-12-31$395.00M
10-K · filed 2026-02-11
2023-12-31$380.00M
10-K · filed 2026-02-11
2022-12-31$360.00M
10-K · filed 2025-02-12
2021-12-31$350.00M
10-K · filed 2024-02-13
2020-12-31$70.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14
$140.00M
derived: sum of 2 quarters · filed 2023-02-14
$205.00M
derived: sum of 3 quarters · filed 2023-02-14
$290.00M
10-K · filed 2023-02-14
2020-09-30$70.00M
10-Q · filed 2020-11-05
$135.00M
derived: sum of 2 quarters · filed 2020-11-05
$220.00M
10-Q · filed 2020-11-05
$280.00M
derived: sum of 4 quarters · filed 2022-02-09
2020-06-30$65.00M
10-Q · filed 2020-08-06
$150.00M
10-Q · filed 2020-08-06
$210.00M
derived: sum of 3 quarters · filed 2022-02-09
$260.00M
derived: sum of 4 quarters · filed 2022-02-09
2020-03-31$85.00M
10-Q · filed 2020-05-07
$145.00M
derived: sum of 2 quarters · filed 2022-02-09
$195.00M
derived: sum of 3 quarters · filed 2022-02-09
$245.00M
derived: sum of 4 quarters · filed 2022-02-09
2019-12-31$60.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09
$110.00M
derived: sum of 2 quarters · filed 2022-02-09
$160.00M
derived: sum of 3 quarters · filed 2022-02-09
$200.00M
10-K · filed 2022-02-09
2019-09-30$50.00M
10-Q · filed 2020-11-05
$100.00M
derived: sum of 2 quarters · filed 2020-11-05
$140.00M
10-Q · filed 2020-11-05
$210.00M
derived: sum of 4 quarters · filed 2021-02-10
2019-06-30$50.00M
10-Q · filed 2020-08-06
$90.00M
10-Q · filed 2020-08-06
$160.00M
derived: sum of 3 quarters · filed 2021-02-10
$210.00M
derived: sum of 4 quarters · filed 2021-02-10
2019-03-31$40.00M
10-Q · filed 2020-05-07
$110.00M
derived: sum of 2 quarters · filed 2021-02-10
$160.00M
derived: sum of 3 quarters · filed 2021-02-10
$210.00M
derived: sum of 4 quarters · filed 2021-02-10
2018-12-31$70.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-10
$120.00M
derived: sum of 2 quarters · filed 2021-02-10
$170.00M
derived: sum of 3 quarters · filed 2021-02-10
$200.00M
10-K · filed 2021-02-10
2018-09-30$50.00M
10-Q · filed 2019-10-31
$49.00M
10-Q · filed 2018-10-25
$100.00M
derived: sum of 2 quarters · filed 2019-10-31
$130.00M
10-Q · filed 2019-10-31
$134.00M
10-Q · filed 2018-10-25
$198.00M
derived: sum of 4 quarters · filed 2020-02-24
2018-06-30$50.00M
10-Q · filed 2019-07-25
$47.00M
10-Q · filed 2018-07-26
$90.00M
10-Q · filed 2019-07-25
$148.00M
derived: sum of 3 quarters · filed 2020-02-24
$194.00M
derived: sum of 4 quarters · filed 2020-02-24
2018-03-31$40.00M
10-Q · filed 2019-04-25
$98.00M
derived: sum of 2 quarters · filed 2020-02-24
$144.00M
derived: sum of 3 quarters · filed 2020-02-24
$196.00M
derived: sum of 4 quarters · filed 2020-02-24
2017-12-31$58.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24
$104.00M
derived: sum of 2 quarters · filed 2020-02-24
$156.00M
derived: sum of 3 quarters · filed 2020-02-24
$200.00M
10-K · filed 2020-02-24
2017-09-30$46.00M
10-Q · filed 2018-10-25
$98.00M
derived: sum of 2 quarters · filed 2018-10-25
$142.00M
10-Q · filed 2018-10-25
$197.00M
derived: sum of 4 quarters · filed 2019-02-25
2017-06-30$52.00M
10-Q · filed 2018-07-26
$96.00M
10-Q · filed 2017-07-27
$151.00M
derived: sum of 3 quarters · filed 2019-02-25
$200.00M
derived: sum of 4 quarters · filed 2019-02-25
2017-03-31$40.00M
10-Q · filed 2018-04-26
$44.00M
10-Q · filed 2017-04-27
$99.00M
derived: sum of 2 quarters · filed 2019-02-25
$148.00M
derived: sum of 3 quarters · filed 2019-02-25
$198.00M
derived: sum of 4 quarters · filed 2019-02-25
2016-12-31$59.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25
$108.00M
derived: sum of 2 quarters · filed 2019-02-25
$158.00M
derived: sum of 3 quarters · filed 2019-02-25
$200.00M
10-K · filed 2019-02-25
$190.00M
10-K · filed 2017-02-21
2016-09-30$49.00M
10-Q · filed 2017-10-26
$99.00M
derived: sum of 2 quarters · filed 2017-10-26
$141.00M
10-Q · filed 2017-10-26
$199.00M
derived: sum of 4 quarters · filed 2018-02-13
2016-06-30$50.00M
10-Q · filed 2017-07-27
$92.00M
10-Q · filed 2017-07-27
$150.00M
derived: sum of 3 quarters · filed 2018-02-13
$203.00M
derived: sum of 4 quarters · filed 2018-02-13
2016-03-31$42.00M
10-Q · filed 2017-04-27
$100.00M
derived: sum of 2 quarters · filed 2018-02-13
$153.00M
derived: sum of 3 quarters · filed 2018-02-13
$198.00M
derived: sum of 4 quarters · filed 2018-02-13
2015-12-31$58.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13
$111.00M
derived: sum of 2 quarters · filed 2018-02-13
$156.00M
derived: sum of 3 quarters · filed 2018-02-13
$200.00M
10-K · filed 2018-02-13
$190.00M
10-K · filed 2016-02-12
2015-09-30$53.00M
10-Q · filed 2016-10-27
$98.00M
derived: sum of 2 quarters · filed 2016-10-27
$142.00M
10-Q · filed 2016-10-27
$191.00M
derived: sum of 4 quarters · filed 2017-02-21
2015-06-30$45.00M
10-Q · filed 2016-07-28
$89.00M
10-Q · filed 2016-07-28
$138.00M
derived: sum of 3 quarters · filed 2017-02-21
$183.00M
derived: sum of 4 quarters · filed 2017-02-21
2015-03-31$44.00M
10-Q · filed 2016-04-28
$93.00M
derived: sum of 2 quarters · filed 2017-02-21
$138.00M
derived: sum of 3 quarters · filed 2017-02-21
$184.00M
derived: sum of 4 quarters · filed 2017-02-21
2014-12-31$49.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21
$94.00M
derived: sum of 2 quarters · filed 2017-02-21
$140.00M
derived: sum of 3 quarters · filed 2017-02-21
$190.00M
10-K · filed 2017-02-21
2014-09-30$45.00M
10-Q · filed 2015-10-27
$91.00M
derived: sum of 2 quarters · filed 2015-10-27
$141.00M
10-Q · filed 2015-10-27
2014-06-30$46.00M
10-Q · filed 2015-07-23
$96.00M
10-Q · filed 2015-07-23
2014-03-31$50.00M
10-Q · filed 2015-04-28
2013-12-31$190.00M
10-K · filed 2016-02-12
2012-12-31$190.00M
10-K · filed 2015-02-13
2011-12-31$181.00M
10-K · filed 2014-02-14
2010-12-31$188.00M
10-K · filed 2013-02-15
2009-12-31$50.00M
10-K · filed 2012-02-17

Similar stocks

Stock NameCountryMarket CapPE Ratio
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
PFIZER INC (PFE)United States$162.042B31.94
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64